Biologically-adapted, dose-escalated radiotherapy for Ewing sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This approach adapts radiotherapy dose based on tumor size and tumor-specific characteristics, using higher-than-standard doses and, in some cases, hypofractionation to concentrate treatment into a shorter schedule. Treatment is delivered with modern imaging guidance and is integrated with standard chemotherapy and surgical options as clinically indicated. The protocol also collects blood and biopsy specimens for correlative research and, for a subset, genomic tumor profiling. The goal is to improve local tumor control while monitoring for side effects and feasibility in a multi-modality treatment plan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
* Patients of age ≥ 2 years are eligible for the study
* Lansky or Karnofsky performance status ≥ 70
* Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
* Willing to provide blood samples for correlative research purposes
* Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is \>= 8 cm

Exclusion Criteria:

* Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes

  * Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
* Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
* Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
* Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
* Any of the following:

  * Pregnant patients
  * Nursing patients

Where it's running

• Mayo Clinic in Arizona
  Phoenix, Arizona, United States Recruiting
• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Roman O. Kowalchuk, MD — Mayo Clinic in Rochester
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dynamic ProGRP Changes During Ewing Sarcoma Treatment

  This study tests whether changes in serum ProGRP levels over time reflect how well newly diagnosed Ewing sarcoma responds to treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07725783

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

• Hypofractionated radiation plus B7-H3 CAR T cells for children and young adults with relapsed sarcoma

  This will test whether short-course radiation given before B7-H3 CAR T-cell therapy is safe for children and young adults (≤21) with relapsed or refractory B7-H3–positive sarcomas.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.